# A useful treatment result changes something you can feel or do *Clear Treatment Claims — Non-surgical Joint Treatment Gilbert* > How to judge non-surgical joint treatment Gilbert claims by asking about relief, risks, cost and useful daily change. ## Gilbert golf makes turning and walking easy measures of relief Gilbert golfers can judge soreness by walking, turning the body and sleeping that night. A treatment is useful when one of those parts of the day gets easier. A lower score on a study form may sound good, but the change still needs to be large enough to feel. Walking, reaching and sleep give relief a plain meaning. ## A fair test asks whether daily life improved enough to notice Joint soreness rises and falls. Rest, extra attention and a lighter week can all help. A fair study compares a treatment with another choice or a harmless shot. People may agree not to learn which shot they received until the study ends. That setup helps show whether the material in the shot added relief. A tiny score change can pass a math test yet still be too small to feel. The useful result is simpler: people walked farther, slept better or used an arm more easily. Ask how many people felt that much change, how long it lasted and what risks occurred. ## Cost and risk belong beside the chance of relief A clinic may charge the patient directly when a procedure isn't covered. That tells you who pays. It doesn't show whether the treatment will help. Get the full price in writing, including planned return visits and any later care. The bill and the chance of relief answer different questions. Ask what the exam found and why the proposed care matches it. The answer should include likely relief, how long it may last and known risks. Ask what the doctor would do if it doesn't help. Be wary when anyone predicts your result before examining the sore joint. ## Sources 1. The RESTORE trial randomised 288 community-based participants aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence grade 2 or 3) to three weekly intra-articular injections of leukocyte-poor PRP or saline placebo, with participants, injectors and assessors all blinded. 93% completed the 12-month follow-up. PRP did not produce a clinically meaningful improvement in knee pain over placebo, and did not slow medial tibial cartilage volume loss on MRI. Bennell KL, Paterson KL, Metcalf BR, et al. — [Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/34812863/). *JAMA*, 2021. DOI: 10.1001/jama.2021.19415. 2. A systematic review and meta-analysis of 169 randomised trials (21,163 participants) of viscosupplementation for knee OA found clear evidence of small-study effects and publication bias. The prespecified main analysis, restricted to 24 large placebo-controlled trials with at least 100 participants per group (8,997 randomised), found a pain reduction of SMD -0.08 (95% CI -0.15 to -0.02) - the confidence interval excluding the prespecified minimal clinically important difference of -0.37. Pereira TV, Jüni P, Saadat P, et al. — [Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis.](https://pubmed.ncbi.nlm.nih.gov/36333100/). *BMJ*, 2022. DOI: 10.1136/bmj-2022-069722. 3. A meta-analysis of 16 randomised trials (807 participants) of intra-articular mesenchymal stem cells for chronic knee pain from osteoarthritis found that at 3-6 months MSC therapy probably produces little to no difference in pain (WMD -0.74cm on a 10cm VAS, 95% CI -1.16 to -0.33, against a minimally important difference of 1.5cm) or physical function, both moderate certainty; at 12 months, probably little to no difference in pain. MSC therapy may increase the risk of any adverse event (RR 2.67, 95% CI 1.19 to 5.99) and of knee pain and swelling (RR 1.58, 95% CI 1.04 to 2.38). Sadeghirad B, Rehman Y, Khosravirad A, et al. — [Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials.](https://pubmed.ncbi.nlm.nih.gov/38777213/). *Osteoarthritis and Cartilage*, 2024. DOI: 10.1016/j.joca.2024.04.021. 4. FDA states directly that regenerative medicine therapies - including stem cells, stromal vascular fraction, umbilical cord blood, amniotic fluid, Wharton's jelly, ortho-biologics and exosomes - have NOT been approved for the treatment of any orthopedic condition, naming osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain. FDA further states that being charged for these products, or being offered them outside an FDA-overseen clinical trial, means a patient is likely being deceived and offered a product illegally, and that a product's presence on clinicaltrials.gov or a firm's FDA registration does not mean the product is legally marketed. Reported harms include blindness, tumor formation, neurological events and life-threatening bacterial infections. US Food and Drug Administration, Center for Biologics Evaluation and Research — [Important Patient and Consumer Information About Regenerative Medicine Therapies](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies). *FDA.gov*, 2021. 5. In the only randomised controlled trial to compare total knee replacement directly with non-surgical treatment in patients already eligible for surgery (n=100), the replacement group improved more at 12 months than the non-surgical group (KOOS4 32.5 vs 16.0; adjusted mean difference 15.8, 95% CI 10.0 to 21.5) but had four times the serious adverse events (24 vs 6, P=0.005). Only 13 of 50 patients (26%) assigned to non-surgical treatment alone had undergone knee replacement by 12 months. Skou ST, Roos EM, Laursen MB, et al. — [A Randomized, Controlled Trial of Total Knee Replacement.](https://pubmed.ncbi.nlm.nih.gov/26488691/). *New England Journal of Medicine*, 2015. DOI: 10.1056/NEJMoa1505467. 6. At 2 years across two parallel randomised trials (200 patients, mean age 66), total knee replacement plus non-surgical treatment beat non-surgical treatment alone by 18.3 KOOS points (95% CI 11.3 to 25.3), and non-surgical treatment in turn beat written advice by 7.0 points (95% CI 0.4 to 13.5). Among patients eligible for replacement, 16 of 50 (32%) in the non-surgical group had surgery within 2 years - meaning two out of three delayed it for at least two years. Skou ST, Roos EM, Laursen MB, et al. — [Total knee replacement and non-surgical treatment of knee osteoarthritis: 2-year outcome from two parallel randomized controlled trials.](https://pubmed.ncbi.nlm.nih.gov/29723634/). *Osteoarthritis and Cartilage*, 2018. DOI: 10.1016/j.joca.2018.04.014. ## A joint exam comes before treatment choices At the Chandler office, QC Kinetix medical providers—health workers who examine joints and perform care—offer regenerative treatments for soreness, using material prepared from the body. The address is 1100 S. Dobson Rd., Suite 210, Chandler, AZ 85286, and the local number is (602) 837-PAIN. Book a free consultation: --- Clear help for a sore joint. A brief Gilbert report on aching joints, sensible relief and signs that need an exam. Plain Gilbert guidance for understanding joint soreness and discussing the next care choice. This site is operated by the local owners whose QC Kinetix clinics serve the Phoenix area, including the Chandler office presented here; a consultation booked through these pages may benefit their clinic business. © 2026 Gilbert Joint List. General joint-care education only; personal decisions need an assessment by a qualified clinician.